Sanofi (SNY) announced that the FDA has approved its lixisenatide, branded as Adlyxin, as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes. Lixesenatide is a once-daily injectable mealtime GLP-1 receptor agonist. GLP-1 is a naturally occurring peptide hormone that is released shortly after eating a meal. It suppresses glucagon secretion from the pancreatic alpha cells and stimulates glucose-dependent insulin secretion by the pancreatic beta cells. Lixisenatide increases glucose-dependent insulin release, decreases glucagon secretion and slows gastric emptying.